NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression.

NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression.
复制标题

NF-κB诱导激酶是NF-κB非经典途径的中心信号传导成分,有助于卵巢癌的进展。

DOI:
10.1371/journal.pone.0088347
复制
发表时间:
2014
期刊:
影响因子:
3.7
通讯作者:
Yamaoka S
Yamaoka S
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Uno M;Saitoh Y;Mochida K;Tsuruyama E;Kiyono T;Imoto I;Inazawa J;Yuasa Y;Kubota T;Yamaoka S

文献摘要

参考文献

被引文献

相似文献

卵巢癌是女性死亡的主要原因之一,迫切需要开发新的治疗方法。核因子-κB(NF-κB)在包括卵巢癌在内的几种类型的癌症中被组成性激活,并且已知其支持癌细胞的存活。然而,NF-κB在卵巢癌中持续活化的分子机制仍不清楚。我们在此报道,除了先前报道的经典激活,NF-κB在卵巢癌细胞中通过非经典途径被激活。RNA干扰介导的NF-κB诱导激酶(NIK)沉默可降低NF-κB2/p52 DNA结合活性、NF-κ B依赖性报告基因表达以及NF-κB靶基因表达。值得注意的是,锚定依赖性和非依赖性细胞生长受损的NIK-耗尽的细胞。在裸鼠异种移植试验中,NIK的耗尽也抑制肿瘤形成。这些结果表明,NIK在组成性NF-κB活化和卵巢癌细胞的进展中起关键作用,并表明NIK代表卵巢癌的有吸引力的治疗靶点。
Ovarian cancer is one of the leading causes of female death and the development of novel therapeutic approaches is urgently required. Nuclear factor-κB (NF-κB) is constitutively activated in several types of cancer including ovarian cancer and is known to support the survival of cancer cells. However, molecular mechanisms of persistent activation of NF-κB in ovarian cancer remain largely unknown. We report here that, in addition to the previously reported canonical activation, NF-κB is activated through the noncanonical pathway in ovarian cancer cells. RNA interference-mediated silencing of NF-κB inducing kinase (NIK), a central regulator of the noncanonical pathway, reduced the NF-κB2/p52 DNA binding activity and NF-κB-dependent reporter gene expression as well as NF-κB target gene expression. Notably, anchorage-dependent and -independent cell growth was impaired in NIK-depleted cells. Depletion of NIK also suppressed tumor formation in the nude mouse xenograft assay. These results indicate that NIK plays a key role in constitutive NF-κB activation and the progression of ovarian cancer cells and suggest that NIK represents an attractive therapeutic target for ovarian cancer.
DOI: 10.1158/1541-7786.mcr-09-0296
发表时间: 2010-03-01
影响因子: 5.2
作者:
Fritz, Rafael D.;Radziwill, Gerald
通讯作者: Radziwill, Gerald
DOI: 10.18632/oncotarget.622
发表时间: 2012-09
期刊: Oncotarget
影响因子: --
作者:
Asangani IA;Harms PW;Dodson L;Pandhi M;Kunju LP;Maher CA;Fullen DR;Johnson TM;Giordano TJ;Palanisamy N;Chinnaiyan AM
通讯作者: Chinnaiyan AM
DOI: 10.1158/0008-5472.can-06-4567
发表时间: 2007-08-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Kikuchi, Ryoko;Tsuda, Hitoshi;Imoto, Issei
通讯作者: Imoto, Issei
DOI: 10.1093/nar/17.13.5245
发表时间: 1989-07-11
影响因子: 14.9
作者:
ISRAEL, A;YANO, O;KOURILSKY, P
通讯作者: KOURILSKY, P
DOI: 10.1182/blood-2007-09-110635
发表时间: 2008-05-15
期刊: BLOOD
影响因子: 20.3
作者:
Saitoh, Yasunori;Yamamoto, Norio;Yamaoka, Shoji
通讯作者: Yamaoka, Shoji